Markers of Ultrasound, Immunologic & Serum Factors in the Comprehensive Analysis of Risks for Early Pregnancy Loss.

Orthogyn Medical Center, Bulgaria1 site in 1 country200 target enrollmentJune 20, 2020

ConditionsSpontaneous Abortion

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Spontaneous Abortion
Sponsor: Orthogyn Medical Center, Bulgaria
Enrollment: 200
Locations: 1
Primary Endpoint: Occurence of a spontaneous abortion
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to determine the role of serum biomarkers and placental bloodflow in the comprehensive evaluation of the risk for spontaneous abortion

Detailed Description

To study the added value (if any) of combining serum markers, immunologic factors, and ultrasound parameters in comprehensively evaluating the risk for spontaneous abortion.

Registry

clinicaltrials.gov

Start Date

June 20, 2020

End Date

December 1, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Orthogyn Medical Center, Bulgaria

Responsible Party

Principal Investigator

Petar Ignatov

Assist. Prof. Petar Ignatov, MD, Ph.D.

Orthogyn Medical Center, Bulgaria

Eligibility Criteria

Inclusion Criteria

•visualized fetal structures in utero \& heart pulsations until 8th week of gestation
•normal THS/T4 levels
•no uterine malformations
•BMI \< 27
•signed informed consent